Search This Blog

Monday, May 28, 2018

Array to update on Phase 3 of melanoma trial at ASCO June 4

Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present data from the Phase 3 COLUMBUS trial of encorafenib and binimetinib in advanced BRAF-mutant melanoma in an oral presentation on June 4, 2018, at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
“Binimetinib and encorafenib is the first targeted therapy to demonstrate over 30 months median overall survival in a Phase 3 trial and we look forward to presenting the results from the COLUMBUS trial at ASCO,” said Ron Squarer, Chief Executive Officer. “With nearly 15 months median progression-free survival and an attractive tolerability profile, these data underscore the potential of this combination to become an important new treatment option for patients with BRAF-mutant advanced, unresectable or metastatic melanoma.”
As previously announced, the most common Grade 3/4 adverse events (AEs) seen in more than 5% of patients were increased gamma-glutamyltransferase (GGT) (9%), increased creatine phosphokinase (7%), and hypertension (6%) in the encorafenib plus binimetinib group.
Oral Presentation:
Title:
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Presenter:
Reinhard Dummer, M.D.
Abstract:
Abstract #223875/Publication #9504
Session:
Melanoma/Skin Cancers
Date:
Monday, June 4, 2018
Time:
9:12 a.m. – 9:24 a.m. Central Time (10:12 a.m. – 10:24 a.m. Eastern Time)
Location:
Arie Crown Theater
The abstract can be accessed through the ASCO website, http://abstract.asco.org/, beginning May 16, 2018, at 5:00 p.m. Eastern Time. Following the presentation on June 4, the slides will be available as a PDF on Array’s website at http://www.arraybiopharma.com.
Array will host an encore webcast presentation of the COLUMBUS trial data.
Encore Webcast:
Date:
Monday, June 4, 2018
Time:
11:15 a.m. Central Time (12:15 p.m. Eastern Time)
Toll-Free:
(844) 464-3927
Toll:
(765) 507-2598
Pass Code:
9615719
Webcast, including replay and conference call slides: https://edge.media-server.com/m6/p/8juh6tcn

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.